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References
• HIV trained pharmacists improve patient care and 
improve outcomes when directly involved.
• Key roles for Pharmacists in HIV care
• Optimizing medications for safety > other reasons
• “Upgrading” regimens to avoid ADRs
• Mitigating current/possible drug interactions
• Decreasing pill burden
• All pharmacists should screen for drug interactions 
with HIV medications.
Future Considerations
• More training in HIV+ care for non-specialized 
pharmacists
• Increasing accessibility to PrEP and PEP via non-
specialized pharmacists
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Results
• HIV care receives regular updates for medications and 
laboratory tests.
• HIV medications have many drug-drug interactions 
and unique side effects that do not usually follow a 
class effect. 
• Many Medication Assistance Programs (MAPs) exist 
for HIV care.
• Pharmacists are specially trained to mitigate drug-drug 
interactions, to avoid side effects, and to reduce pill 
burden.
• Pharmacist led HIV care improves anti-retroviral 
therapy (ART) adherence rates. 
• HIV viral load (VL) and CD4+ cell counts improve with 
greater pharmacist involvement in HIV management.
• New collaborative practice agreement (CPA) for HIV 
was established at Providence in September 2018.
• Retrospective chart-review
• Primary Endpoint: composite of ART changes for 
genotype results, safety (interactions, side effects), 
and pill burden
• Quantitative statistics utilized
• IRB granted exempt status
• Primary: Evaluate clinical impact of an HIV specialist 
pharmacist CPA on patient care
• Composite of ART changes for genotype results, 
safety (interactions, side effects), and pill burden
• Secondary: 
• Number of visits for HIV/AIDS, PrEP, and PEP
• Number of MAP interventions
• HIV VL and CD4+ count changes over time
• No change = VL and CD4+ count kept within goal
• Improved = VL ↓; CD4+ count ↑
• Worsened = VL ↑; CD4+ count ↓
• Co-morbid disease state medication modifications
• Number of Coordination of Care interventions
Current Guidelines
• Non-pregnant: 2 NRTIs + 1 INSTI 
• Pregnant: continue current regimen, RAL + 2 NRTIs (all 
trimesters), or DTG + 2 NRTIs (2nd, 3rd trimesters) 
Table 2. Primary Endpoint (All Patients, N = 100)
No Change 27 (27%)
Composite 73 (73%)
Safety (drug interactions, side effects) 49 (67%)• Example: EFV → BIC = 14
Safety + PB 5 (7%)
Pill Burden (PB) 13 (18%)
Genotype + PB 2 (3%)
Genotype Results 4 (5%)
Study Limitations
• No statistical analysis
• Small sample size
• Did not collect race/ethnicity data
• Not all patients analyzed (total number seen = 224)
• Pharmacist role may be primarily in improving ART 
safety.
• Updating regimens to avoid adverse drug reactions
• Detecting and mitigating drug interactions
• Possibly less emphasis on pill burden than in the past
• ART changes can be made for more than one reason.
• Pharmacists may have more time than ID physicians 
for f/u, improving engagement, and enrolling patients 
in MAPs.
• Especially for PEP and PrEP
• Patient outcomes were improved since PharmD 
actively managed care instead of made 
recommendations.
Table 1. Patient Demographics (N=100)
Age, mean (range) 49 years (21-83)
Biological Sex 93% male
Gender Identity 1% trans-female
Abbreviations
Brand Name Individual Agents
Biktarvy: BIC/TAF/FTC
Atripla: EFV/TDF/FTC
Truvada: TDF/FTC
BIC: Bictegravir
DTG: Dolutegravir
RAL: Raltegravir
TDF: tenofovir disoproxil fumarate
TAF: tenofovir alafenamide
FTC: emtricitabine
EFV: efavirenz
Table 4. Secondary Endpoints (HIV+ Patients, N=75)
Level of Control Overall Average
HIV Viral Load
(Goal <20)
No change = 54
Improved = 13
Worsened = 6
Lost to follow-up = 2
Number of patients at goal (Pre-PharmD) = 58
Number of patients at goal (Post) = 63
Average VL Pre → Post-PharmD = 2054 → 298
CD4+ Count
(Goal ≥200)
No change = 57
Improved = 2
Worsened = 0
Lost to follow-up = 16
Number of patients at goal (Pre-PharmD) = 72
Number of patients at goal (Post) = 74
Average CD4+ Pre → Post-PharmD = 618 → 690
Type of Change Examples
Co-morbid Disease State 
Medication Modifications
Started = 4
Stopped = 3
Modified = 2
• Decreased metformin to 1000 mg/day due to 
DTG interaction
• Changed intranasal steroid due to COBI 
interaction
Coordination of Care 
Interventions 7
• Worked with ID physician to order DEXA
• Wrote detailed birth plan
Table 3. Secondary Endpoints (All Patients, N=100)
HIV/AIDS Visits 75
PEP Visits 18
PrEP Visits 7
MAP Enrollments 49
73%
27%
Safety, 67%
PB, 18%
Genotype + PB, 3%
Genotype, 5%Safety + PB, 7%
Figure 1. Anti-Retroviral Therapy Modifications and Rationale for Change 
(All Patients, N = 100)
